The official journal of the Japanese Society for Vaccinology, Vaccine, released a special issue highlighting the National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs). This issue features research advances from the CIVICs program and a commentary from NIAID leaders describing the program’s origin and goals.
CIVICs research is conducted and supported by over fifty academic, government, and industry partners. The three research centers (CIVR-HRP, DCVC, and SEM CIVIC) deploy talented research teams to develop a variety of vaccine platforms in pre-clinical models. The CIVICs Vaccine Manufacturing and Toxicology Core works closely with the research centers to manufacture vaccines for evaluation by the two Clinical Cores (Duke and UMB) in clinical trials and human challenges studies, while the Statistical, Data Management, and Coordination Center (SDMCC) provides support across CIVICs to enable research and dissemination of network information and scientific data. By combining the efforts of these diverse organizations, NIAID continues progress towards a universal influenza vaccine.
-
Improving immunogenicity and durability of influenza vaccines
-
Developing iterative vaccine approaches for broad protection
-
Assessing vaccines in preclinical, clinical, and human challenge studies
Read the full Vaccine special issue or view the commentary and other articles linked here to learn more about CIVICs-funded vaccine studies and promising influenza vaccine advances.
Collaborative influenza vaccine innovation centers (CIVICs) program
Singleton and Post et al. (NIAID)
Combination of recombinant neuraminidase with cHA-based inactivated split vaccines improves the breadth of cross-reactivity and protection against influenza viruses in mice
Puente-Massaguer and Vasilev et al. (SEM CIVIC)
DNA co-delivery of seasonal H1 influenza hemagglutinin nanoparticle vaccines with chemokine adjuvant CTACK induces potent immunogenicity for heterologous protection in vivo
Liaw and Konrath et al. (SEM CIVIC)
Exploring bias due to below-limit-of-detection values in influenza vaccine antibody modeling: A case study and instructional guide for the CIVIC study
Ge et al. (CIVR-HRP)
Fluorescence-barcoded cell lines stably expressing membrane-anchored influenza neuraminidases
Finney et al. (DCVC)
Impact of age and prior COVID-19 on the response to influenza A components in the 2020–2021 Fluzone vaccine
Ashraf and Lee et al. (SEM CIVIC)
Live-attenuated pandemic H1N1 influenza vaccines expressing computationally optimized broadly reactive antigens (COBRAs) are immunogenic and protective in mice and ferrets
Chen et al. (SEM CIVIC)
Multivalent H3 COBRA-based influenza vaccine elicits enhanced immune response in a pre-immune elderly ferret model
Zhang et al. (CIVR-HRP)